End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
33.47 CNY | +2.04% | +3.40% | +11.98% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 61% by 2026.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.8 for the current period. Therefore, the company is undervalued.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.98% | 2.7B | C+ | ||
-9.92% | 3.66B | D+ | ||
-0.84% | 3.35B | D- | ||
-23.44% | 3.05B | D | ||
+7.77% | 2.65B | - | ||
-9.85% | 1.71B | - | ||
+11.09% | 1.37B | - | - | |
-19.60% | 971M | - | ||
-37.98% | 709M | - | - | |
-0.53% | 453M | - | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603883 Stock
- Ratings LBX Pharmacy Chain